139 related articles for article (PubMed ID: 17453622)
1. Heparan sulfate as a therapeutic target in amyloidogenesis: prospects and possible complications.
Kisilevsky R; Ancsin JB; Szarek WA; Petanceska S
Amyloid; 2007 Mar; 14(1):21-32. PubMed ID: 17453622
[TBL] [Abstract][Full Text] [Related]
2. Binding of heparan sulfate glycosaminoglycan to beta-amyloid peptide: inhibition by potentially therapeutic polysulfated compounds.
Leveugle B; Scanameo A; Ding W; Fillit H
Neuroreport; 1994 Jun; 5(11):1389-92. PubMed ID: 7522615
[TBL] [Abstract][Full Text] [Related]
3. Induction of perlecan gene expression precedes amyloid formation during experimental murine AA amyloidogenesis.
Ailles L; Kisilevsky R; Young ID
Lab Invest; 1993 Oct; 69(4):443-8. PubMed ID: 8231112
[TBL] [Abstract][Full Text] [Related]
4. In vivo fragmentation of heparan sulfate by heparanase overexpression renders mice resistant to amyloid protein A amyloidosis.
Li JP; Galvis ML; Gong F; Zhang X; Zcharia E; Metzger S; Vlodavsky I; Kisilevsky R; Lindahl U
Proc Natl Acad Sci U S A; 2005 May; 102(18):6473-7. PubMed ID: 15843464
[TBL] [Abstract][Full Text] [Related]
5. Macromolecules that are colocalized with deposits of beta 2-microglobulin in hemodialysis-associated amyloidosis.
Aruga E; Ozasa H; Teraoka S; Ota K
Lab Invest; 1993 Aug; 69(2):223-30. PubMed ID: 8394479
[TBL] [Abstract][Full Text] [Related]
6. Novel glycosaminoglycan precursors as anti-amyloid agents part II.
Kisilevsky R; Szarek WA
J Mol Neurosci; 2002; 19(1-2):45-50. PubMed ID: 12212792
[TBL] [Abstract][Full Text] [Related]
7. Proteoglycans and amyloid fibrillogenesis.
Kisilevsky R; Fraser P
Ciba Found Symp; 1996; 199():58-67; discussion 68-72, 90-103. PubMed ID: 8915604
[TBL] [Abstract][Full Text] [Related]
8. Amyloidogenesis recapitulated in cell culture: a peptide inhibitor provides direct evidence for the role of heparan sulfate and suggests a new treatment strategy.
Elimova E; Kisilevsky R; Szarek WA; Ancsin JB
FASEB J; 2004 Nov; 18(14):1749-51. PubMed ID: 15345688
[TBL] [Abstract][Full Text] [Related]
9. Effect of poly(vinylsulfonate) on murine AA amyloid: a high-resolution ultrastructural study.
Inoue S; Hultin PG; Szarek WA; Kisilevsky R
Lab Invest; 1996 Jun; 74(6):1081-90. PubMed ID: 8667612
[TBL] [Abstract][Full Text] [Related]
10. In vivo analysis of murine serum sulfate metabolism and splenic glycosaminoglycan biosynthesis during acute inflammation and amyloidosis.
Lyon AW; Anastassiades T; Kisilevsky R
J Rheumatol; 1993 Jul; 20(7):1108-13. PubMed ID: 8371201
[TBL] [Abstract][Full Text] [Related]
11. Characterization of splenic glycosaminoglycans accumulated in vivo in experimentally induced amyloid-susceptible and amyloid-resistant mice.
Sugumaran G; Elliott-Bryant R; Phung N; Vitseva O; Kuberan B; Lech M
Scand J Immunol; 2004 Dec; 60(6):574-83. PubMed ID: 15584968
[TBL] [Abstract][Full Text] [Related]
12. Heparan sulfate proteoglycans in amyloidosis.
Zhang X; Li JP
Prog Mol Biol Transl Sci; 2010; 93():309-34. PubMed ID: 20807650
[TBL] [Abstract][Full Text] [Related]
13. Amyloid formation by pro-islet amyloid polypeptide processing intermediates: examination of the role of protein heparan sulfate interactions and implications for islet amyloid formation in type 2 diabetes.
Meng F; Abedini A; Song B; Raleigh DP
Biochemistry; 2007 Oct; 46(43):12091-9. PubMed ID: 17924651
[TBL] [Abstract][Full Text] [Related]
14. Molecular chaperons, amyloid and preamyloid lesions in the BRI2 gene-related dementias: a morphological study.
Lashley T; Holton JL; Verbeek MM; Rostagno A; Bojsen-Møller M; David G; van Horssen J; Braendgaard H; Plant G; Frangione B; Ghiso J; Revesz T
Neuropathol Appl Neurobiol; 2006 Oct; 32(5):492-504. PubMed ID: 16972883
[TBL] [Abstract][Full Text] [Related]
15. Review: amyloidogenesis-unquestioned answers and unanswered questions.
Kisilevsky R
J Struct Biol; 2000 Jun; 130(2-3):99-108. PubMed ID: 10940218
[TBL] [Abstract][Full Text] [Related]
16. Inhibition of amyloid A amyloidogenesis in vivo and in tissue culture by 4-deoxy analogues of peracetylated 2-acetamido-2-deoxy-alpha- and beta-d-glucose: implications for the treatment of various amyloidoses.
Kisilevsky R; Szarek WA; Ancsin JB; Elimova E; Marone S; Bhat S; Berkin A
Am J Pathol; 2004 Jun; 164(6):2127-37. PubMed ID: 15161647
[TBL] [Abstract][Full Text] [Related]
17. Implications of Heparan Sulfate and Heparanase in Amyloid Diseases.
Li JP; Zhang X
Adv Exp Med Biol; 2020; 1221():631-645. PubMed ID: 32274729
[TBL] [Abstract][Full Text] [Related]
18. What role(s) may extracellular matrix, particularly heparan sulfate, play in amyloid of Alzheimer's disease.
Benditt EP
Neurobiol Aging; 1989; 10(5):506; discussion 510-2. PubMed ID: 2530463
[TBL] [Abstract][Full Text] [Related]
19. Amyloid and amyloidoses: differences, common themes, and practical considerations.
Kisilevsky R
Mod Pathol; 1991 Jul; 4(4):514-8. PubMed ID: 1924282
[TBL] [Abstract][Full Text] [Related]
20. Tinkering with heparan sulfate sulfation to steer development.
Gorsi B; Stringer SE
Trends Cell Biol; 2007 Apr; 17(4):173-7. PubMed ID: 17320398
[TBL] [Abstract][Full Text] [Related]
[Next] [New Search]
